![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Simeprevir (TMC435) with peginterferon-α-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy in patients with genotype 1b HCV in the PROMISE Phase III trial
|
|
|
Reported by Jules Levin
APASL 2014 March 12-15 Brisbane, Australia
EJ Gane,1 X Forns,2 E Lawitz,3 S Zeuzem,4 JP Bronowicki,5 P Andreone,6 A Horban,7 AS Brown,8 M Peeters,9 O Lenz,9 S Ouwerkerk-Mahadevan,9 R Kalmeijer,10 G De La Rosa,1 R Sinha,9 M Beumont-Mauviel9
1Auckland Hospital Clinical Studies Unit, Auckland, New Zealand; 2Liver Unit, Hospital Clinic, IDIBAPS, CIBEREHD, Barcelona, Spain; 3Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 4J.W. Goethe University Hospital, Frankfurt, Germany; 5INSERM U954, Universite de Lorraine, Centre Hospitalier Universitaire de Nancy, Vandoeuvre Les Nancy, France; 6Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna, Italy; 7Medical University of Warsaw, Wolska, Warsaw, Poland; 8Imperial College Healthcare NHS Trust, London, UK; 9Janssen Infectious Diseases BVBA and Janssen Research & Development, Beerse, Belgium;10Janssen Global Services, LLC, Titusville, NJ, USA
![CROI1.gif](../images/032414/032414-19/CROI1.gif)
![CROI2.gif](../images/032414/032414-19/CROI2.gif)
![CROI3.gif](../images/032414/032414-19/CROI3.gif)
![CROI4.gif](../images/032414/032414-19/CROI4.gif)
![CROI5.gif](../images/032414/032414-19/CROI5.gif)
![CROI6.gif](../images/032414/032414-19/CROI6.gif)
![CROI7.gif](../images/032414/032414-19/CROI7.gif)
![CROI8.gif](../images/032414/032414-19/CROI8.gif)
![CROI9.gif](../images/032414/032414-19/CROI9.gif)
![CROI10.gif](../images/032414/032414-19/CROI10.gif)
![CROI11.gif](../images/032414/032414-19/CROI11.gif)
![CROI12.gif](../images/032414/032414-19/CROI12.gif)
![CROI13.gif](../images/032414/032414-19/CROI13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|